BNP Paribas Financial Markets
JUNO

BNP Paribas Financial Markets’s Juno Therapeutics, Inc. JUNO Stock Holding History

BNP Paribas Financial Markets’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,561
Closed -$711K – 4423
2017
Q4 		$711K Sell
15,561
-7,966
-34% -$397K ﹤0.01% 2225
2017
Q3 		$1.06M Sell
23,527
-1,706
-7% -$58.2K ﹤0.01% 1520
2017
Q2 		$754K Sell
25,233
-3,248
-11% -$80.1K ﹤0.01% 1679
2017
Q1 		$632K Buy
28,481
+8,150
+40% +$175K ﹤0.01% 1606
2016
Q4 		$383K Sell
20,331
-1,873
-8% -$45.8K ﹤0.01% 1830
2016
Q3 		$666K Buy
22,204
+7,526
+51% +$234K ﹤0.01% 1079
2016
Q2 		$564K Sell
14,678
-40,697
-73% -$1.69M ﹤0.01% 1455
2016
Q1 		$2.11M Sell
55,375
-47,037
-46% -$1.64M 0.01% 809
2015
Q4 		$4.5M Buy
102,412
+62,090
+154% +$3.08M 0.01% 658
2015
Q3 		$1.64M Sell
40,322
-199
-0.5% -$8.73K ﹤0.01% 905
2015
Q2 		$2.16M Buy
40,521
+40,301
+18,319% +$2.14M 0.01% 844
2015
Q1 		$13.3K Buy
+220
New +$10.7K ﹤0.01% 2583

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

BNP Paribas Financial Markets's JUNO Position: Q1 2018 in Review

BNP Paribas Financial Markets sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 15,561 shares — an estimated $711K sold.

BNP Paribas Financial Markets first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $4.5M in Q4 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • BNP Paribas Financial Markets reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 15,561 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $711K.
  • BNP Paribas Financial Markets first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • BNP Paribas Financial Markets's Juno Therapeutics, Inc. position peaked at $4.5M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2018, filed 11 May 2018.